BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#60 of 347

Matthew Caufield

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2023No new ratings since Jun 2025

Analyst rating accuracy & track record

Matthew Caufield is an equity research analyst at HC Wainwright & Co.. Bullish Whales has scored 56 of their stock calls across 13 companies. Their picks beat their sector 54% of the time over the next 12 months, and their price targets were reached 35% of the time within a year.

Win % vs sector
54%
PT Hit % (12mo)
35%
Avg sector-excess
+1.8%
Scored calls
56
Tickers
13
Tier
Established

Track record

Bullish Whales has scored 56 of Matthew Caufield's stock calls across 13 companies, dating back to 2023. Their rated stocks beat their own sector 54% of the time over the next 12 months. On a typical call, a Caufield pick returned +1.8% more than its sector over the following year.

Of the scored calls, 56 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
PHATPhathom Pharmaceuticals Inc
Buy$20.00Jun 2025−6.5%Miss
AKBAAkebia Ther
Buy$8.00Jun 2025−90.0%Miss
DMACDiaMedica Therapeutics Inc
Buy$10.00May 2025+31.0%Hit
TARSTarsus Pharmaceuticals Inc
Buy$72.00May 2025+27.6%Hit
ALDXAldeyra The
Buy$10.00May 2025−46.1%Miss
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$42.00May 2025+61.8%Hit
SRZNSurrozen Inc
Buy$32.00May 2025+313.3%Hit
LENZLENZ Therapeutics Inc
Buy$38.00May 2025−71.9%Hit
PHATPhathom Pharmaceuticals Inc
Buy$20.00May 2025+392.2%Miss
IMUXImmunic Inc
Buy$10.00May 2025−22.7%Miss
LENZLENZ Therapeutics Inc
Buy$38.00Apr 2025−69.7%Hit
IMUXImmunic Inc
Buy$10.00Apr 2025+7.4%Miss
ALDXAldeyra The
Buy$10.00Apr 2025−31.7%Miss
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$42.00Apr 2025+94.9%Hit
SRZNSurrozen Inc
Buy$32.00Apr 2025+133.0%Miss
IRDOpus Genetics, Inc.
Buy$8.00Apr 2025+400.1%Miss
FBLGFibroBiologics, Inc. Common Stock
Buy$12.00Apr 2025−97.1%Miss
DMACDiaMedica Therapeutics Inc
Buy$10.00Mar 2025+35.1%Hit
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$30.00Mar 2025+92.1%Hit
PHATPhathom Pharmaceuticals Inc
Buy$28.00Mar 2025+146.2%Miss
ALDXAldeyra The
Buy$10.00Mar 2025−24.8%Miss
FDMT4D Molecular Therapeutics Inc
Buy$36.00Mar 2025+105.5%Miss
IMUXImmunic Inc
Buy$10.00Feb 2025−37.2%Miss
IRDOpus Genetics, Inc.
Buy$8.00Feb 2025+212.9%Miss
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$30.00Feb 2025+158.7%Hit
FBLGFibroBiologics, Inc. Common Stock
Buy$12.00Feb 2025−90.4%Miss
FDMT4D Molecular Therapeutics Inc
Buy$36.00Feb 2025+90.5%Miss
SRZNSurrozen Inc
Buy$32.00Jan 2025+78.5%Miss
FDMT4D Molecular Therapeutics Inc
Buy$36.00Jan 2025+47.1%Miss
PHATPhathom Pharmaceuticals Inc
Buy$28.00Dec 2024+73.3%Miss
IRDOpus Genetics, Inc.
Buy$8.00Dec 2024+120.2%Miss
IMUXImmunic Inc
Buy$10.00Nov 2024−48.5%Miss
DMACDiaMedica Therapeutics Inc
Buy$7.00Nov 2024+45.7%Hit
FDMT4D Molecular Therapeutics Inc
Buy$36.00Nov 2024+13.2%Miss
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$30.00Nov 2024+274.2%Hit
LENZLENZ Therapeutics Inc
Buy$38.00Nov 2024−33.6%Hit
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$30.00Oct 2024+204.4%Hit
DMACDiaMedica Therapeutics Inc
Buy$7.00Oct 2024+62.2%Hit
DMACDiaMedica Therapeutics Inc
Buy$7.00Oct 2024+50.8%Hit
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$30.00Aug 2024+57.4%Miss
LENZLENZ Therapeutics Inc
Buy$38.00Aug 2024+75.8%Hit
PHATPhathom Pharmaceuticals Inc
Buy$28.00Aug 2024−2.9%Miss
LENZLENZ Therapeutics Inc
Buy$38.00Aug 2024+68.6%Hit
ALDXAldeyra The
Buy$10.00Aug 2024+21.8%Miss
ALDXAldeyra The
Buy$10.00Aug 2024+65.4%Miss
MLYSMineralys Therapeutics, Inc. Common Stock
Buy$30.00Jul 2024+13.8%Miss
ALDXAldeyra The
Buy$10.00May 2024−45.4%Miss
LYRALyra Therapeutics Inc
Buy$12.00May 2024−96.4%Miss
ALDXAldeyra The
Buy$10.00Apr 2024+26.5%Miss
LYRALyra Therapeutics Inc
Buy$12.00Mar 2024−100.3%Miss
Go to

Matthew Caufield: analyst track record FAQ

Is Matthew Caufield a good stock analyst?

Yes, by track record. Matthew Caufield ranks number 60 of 347 of the analysts Bullish Whales scores, with a BW Score of 55 out of 100. Past results do not guarantee future ones.

What is Matthew Caufield's win rate?

Matthew Caufield's win rate is 54%. Across 56 scored calls, their rated stocks beat their sector 54% of the time over the next 12 months. On a typical call they returned +1.8% more than the sector.

What stocks and sectors does Matthew Caufield cover?

Matthew Caufield covers 13 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Matthew Caufield's price targets accurate?

Matthew Caufield's price targets are reached within 12 months 35% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Matthew Caufield's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Matthew Caufield rank among Wall Street analysts?

Matthew Caufield ranks number 60 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30